How to battle superbugs with viruses that “eat” them

As antibiotic resistance spreads, bacteriophages could help avert a crisis “Antibiotics are vital to modern medicine. [..] Life expectancy would drop by a third if they did not exist. But after decades of overuse their powers are fading. Some bacteria have evolved resistance, creating a growing army of “superbugs” against which there is no effective treatment. Antimicrobial resistance is expected to kill 10m people a year by 2050, up from around 1m in 2019. [..] Microbiologists have known for decades that disease-causing bacteria can suffer from illnesses of their own. They are susceptible to attack by bacteriophages (“phages” for short): … Read More

Current concepts in coronary artery revascularisation

“More than five decades after the introduction of CABG and four decades after the introduction of PCI into clinical practice, the procedural and long-term outcomes of the two revascularisation methods are now well characterised. Although technological improvements will continue to increase their safety and efficacy, the relative advantages and disadvantages of the two interventions will probably remain substantially unchanged. A limitation of available data is that they are from prevalently young, White, male, HIC [high-income countries] populations. The results of coronary revascularisation in women, non-White racial and ethnic groups, older adults, and LMICs [low- and middle-income countries] require further and … Read More

Beyond Wegovy and Ozempic: Biotechs vie for piece of red-hot weight loss market with novel strategies

“This class of drugs [GLP-1 agonists], though, often causes severe nausea in early weeks and doesn’t lead to significant weight loss in everyone. There’s growing concern that in addition to fat loss, the drugs lead to muscle loss that could prove detrimental for older patients. And for most people, the costly drugs may need to be taken forever to sustain the effects. [..] Versanis’ bimagrumab, which increases muscle while cutting fat, stands out because all currently available obesity drugs lead to muscle loss. In a trial for Wegovy, for example, about 40% of the weight that people lost was lean mass. Some … Read More

Study: Single dose of HPV vaccine up to 98% effective

“A new study from researchers at the Kenya Medical Research Institute (KEMRI) and Massachusetts General Hospital (MGH) showed a single dose of human papillomavirus virus (HPV) vaccine was highly efficacious in preventing HPV, the virus that causes cervical cancer, in girls and women ages 15 to 20. The study results were announced at the 35th International Papillomavirus Conference in Washington, DC, this week. Researchers described the findings from their randomized, multicenter, double-blind, controlled trial, which included 2,275 participants in Kenya between the ages of 15 and 20. The women were randomly assigned to receive either a single dose of the bivalent … Read More

What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a lower carbohydrate diet with weight loss

“we examine real-world data from a cohort based in a UK primary care clinic offering a low-carbohydrate approach to people with T2D [type 2 diabetes] from 2013 to 2021. The physiological mechanisms behind remission induced by dietary weight loss were first demonstrated in 2011. Since then the idea of drug-free T2D remission has gained international momentum. [..] Advice on lowering dietary carbohydrate was offered routinely by our team of nine specially trained GPs and three practice nurses to patients with T2D (defined as HbA1c >48 mmol/mol on two occasions) starting in March 2013. Our protocol includes important information around the deprescribing of … Read More

Aldosterone, a hormone that prevents dehydration, is linked to worsening kidney disease, study suggests

“In the observational study [published in the European Heart Journal on 2022.8.7], researchers analyzed health data from 3,680 people with chronic kidney disease for nearly 10 years. Those with elevated levels of aldosterone, a crucial, salt-conserving hormone made by the adrenal glands, which sit atop the kidneys, had a higher risk of serious kidney disease progression during the study period: they are more likely to lose half their kidney function, start dialysis, or develop end-stage kidney disease. [Excerpts of an interview with Ashish Verma, kidney specialist and assistant professor of medicine at Boston University School of Medicine:] [Verma:] We found … Read More

As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked

“[Nir] Barzilai, the head of the Institute for Aging Research at the Albert Einstein College of Medicine, and scientific director for AFAR — the American Federation for Aging Research — has for more than a decade been leading the charge to test the idea of using drugs to extend human healthspan. In 2013, he and two other researchers got a grant from the National Institutes of Aging to develop a roadmap to conduct, for the first time in history, a clinical trial that targets aging. They planned to test metformin, a drug that had been approved in the ’90s for … Read More

The Quest by Circadian Medicine to Make the Most of Our Body Clocks

Excerpt – In the early 2000s, advances in the ability to detect the activity of genes in various tissues revealed that the cell clocks are organized into separate organ-level clocks representing every physiological system: There’s a skin clock and a liver clock and an immune-system clock; there’s a clock for the kidney, heart, lungs, muscles and reproductive system. Each of those clocks syncs itself to the central clock in the brain like an orchestra section following its conductor. But those sections also adjust how and when they perform based on guidance they receive both from the environment and from one … Read More

Intravenous Fluids—A Test Case for Learning Health Systems

“Explanatory trials evaluating the efficacy and safety of adding a new drug or device to current clinical care (A vs A-plus) are traditionally powered to detect the smallest difference in clinical outcomes that would justify incorporating the new treatment into care, considering its added risks, costs, and burdens. For example, the median minimal clinically important difference in mortality targeted by acute care trials has been approximately 8%, implying that smaller differences in mortality might not justify incorporation of the new treatments into care. These types of trials ask, “is this new treatment better than current care by enough to offset … Read More

Dr. Venture Capital: Insurance companies are supposed to cover high-quality care for patients. What happens when they dabble in investing?

“The insurance companies [Cigna and Kaiser Permanente] provided Ginger with access to millions of potential users. After its financial investments in Ginger, Cigna began offering no-cost access to Ginger’s behavioral health services in order to improve customers’ overall health and well-being, according to leadership from both organizations. Yes, it is possible that those customers will benefit from the platform. But given that Ginger’s valuation grew in multiples around the same time—at least in part because of the massive influx of customers from Cigna and Kaiser—it’s reasonable to suggest that the insurance company was double dipping. By sending its customers to … Read More